Quantified news impact based on deduplicated, quality-reviewed events in a single 200-day window.
Sample note: only 2 qualifying events; only 2 independent sources; impact is highly concentrated in a few events. Metrics may be volatile.
Positive 1 · Negative 0 · Mixed 1
Page 1 of 1 · 2 events
China's market regulator unconditionally approved during July 13-19, 2026 a new joint venture by Hangyang Group and Shandong Haili Chemical, and also cleared Shanghai Pharma E-Health's acquisition of equity in 18 companies, including Shanghai Pharma Yiyao Pharmacy (Huimin).
China's National Medical Products Administration has revised the instructions for Ganmaoling oral liquid preparations, adding warnings including a ban on driving and operating precision instruments. Manufacturers must file updated instructions with provincial drug authorities by October 15, 2026. Huaren Sanjiu's 999 Ganmaoling brand recorded retail sales exceeding RMB 2 billion in 2025. In a related court case, a pharmacy was found 40% liable for dispensing drugs without proper instructions, highlighting the importance of compliance.
No evidence on this page.